This one comes not from our annals but it is interesting.
Patients with UGIB can be very unstable and getting control of that bleeding is a key factor in keeping them alive.
Here is a SR that provides evidence that TXA reduces mortality in these patients.
Compelling given the low complication rates with TXA seen in the CRASH-2 study.
If you want to read a bit more there is a Cochran review by the same group.
The studies included are not great but the HALT trial (read here) is in progress so we should see some better data in the future.
TXA might be moving into that realm of panacea therapies where Mag, ketamine and NIV live?